Matches in SemOpenAlex for { <https://semopenalex.org/work/W1926198890> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W1926198890 endingPage "1011" @default.
- W1926198890 startingPage "1006" @default.
- W1926198890 abstract "Forty-seven patients with recurrent or metastatic head and neck squamous cancer were entered into a prospectively controlled study comparing high-dose infusion methotrexate with leucovorin against standard-dose methotrexate without leucovorin. Patients were stratified for prior treatment and hematogenous metastases prior to randomization. Patients received either methotrexate (1,500 mg/m2) infused over 24 hours with leucovorin or 40 mg/m2 intramuscularly. Each treatment was given weekly for the first six weeks and followed a dose escalation schedule to toxicity. After six weeks patients received the high-dose regimen every two weeks and the low-dose schedule continued weekly. One patient was ineligible and four had inadequate follow-up to assess response (less than two weeks). Forty-two patients were evaluable for survival and 37 for response. Six of 19 patients (32%) treated with high-dose infusion responded (one complete response) and four of 18 patients (22%) receiving standard dosage responded (P = .52). Treatment with high-dose methotrexate resulted in an improved duration of disease control over standard dosage with the respective median times to progression of 11 weeks and five weeks (P = .04). These differences were most marked in good performance status patients (P = .007) and those without hematogenous dissemination (P = .02). Toxicity, however, was also significantly worse in the high-dose treatment group (P = .01) and survival was identical between treatments (4.2 months). The authors conclude that any treatment advantage to high-dose methotrexate may be attributable to its greater toxicity rather than to a selective therapeutic effect and this regimen does not result in improved patient survival. Good performance status patients may benefit from more aggressive therapy." @default.
- W1926198890 created "2016-06-24" @default.
- W1926198890 creator A5003528816 @default.
- W1926198890 creator A5034546553 @default.
- W1926198890 creator A5042345502 @default.
- W1926198890 creator A5061234326 @default.
- W1926198890 creator A5063363315 @default.
- W1926198890 date "1984-09-01" @default.
- W1926198890 modified "2023-09-23" @default.
- W1926198890 title "A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer." @default.
- W1926198890 cites W1491418697 @default.
- W1926198890 cites W1968362080 @default.
- W1926198890 cites W1974907966 @default.
- W1926198890 cites W2076668534 @default.
- W1926198890 cites W2103468907 @default.
- W1926198890 cites W2108109304 @default.
- W1926198890 cites W2408392821 @default.
- W1926198890 doi "https://doi.org/10.1200/jco.1984.2.9.1006" @default.
- W1926198890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6332178" @default.
- W1926198890 hasPublicationYear "1984" @default.
- W1926198890 type Work @default.
- W1926198890 sameAs 1926198890 @default.
- W1926198890 citedByCount "48" @default.
- W1926198890 countsByYear W19261988902014 @default.
- W1926198890 countsByYear W19261988902018 @default.
- W1926198890 countsByYear W19261988902021 @default.
- W1926198890 crossrefType "journal-article" @default.
- W1926198890 hasAuthorship W1926198890A5003528816 @default.
- W1926198890 hasAuthorship W1926198890A5034546553 @default.
- W1926198890 hasAuthorship W1926198890A5042345502 @default.
- W1926198890 hasAuthorship W1926198890A5061234326 @default.
- W1926198890 hasAuthorship W1926198890A5063363315 @default.
- W1926198890 hasConcept C126322002 @default.
- W1926198890 hasConcept C141071460 @default.
- W1926198890 hasConcept C168563851 @default.
- W1926198890 hasConcept C204243189 @default.
- W1926198890 hasConcept C2776530083 @default.
- W1926198890 hasConcept C2776694085 @default.
- W1926198890 hasConcept C2781059491 @default.
- W1926198890 hasConcept C2781413609 @default.
- W1926198890 hasConcept C29730261 @default.
- W1926198890 hasConcept C509974204 @default.
- W1926198890 hasConcept C71924100 @default.
- W1926198890 hasConceptScore W1926198890C126322002 @default.
- W1926198890 hasConceptScore W1926198890C141071460 @default.
- W1926198890 hasConceptScore W1926198890C168563851 @default.
- W1926198890 hasConceptScore W1926198890C204243189 @default.
- W1926198890 hasConceptScore W1926198890C2776530083 @default.
- W1926198890 hasConceptScore W1926198890C2776694085 @default.
- W1926198890 hasConceptScore W1926198890C2781059491 @default.
- W1926198890 hasConceptScore W1926198890C2781413609 @default.
- W1926198890 hasConceptScore W1926198890C29730261 @default.
- W1926198890 hasConceptScore W1926198890C509974204 @default.
- W1926198890 hasConceptScore W1926198890C71924100 @default.
- W1926198890 hasIssue "9" @default.
- W1926198890 hasLocation W19261988901 @default.
- W1926198890 hasLocation W19261988902 @default.
- W1926198890 hasOpenAccess W1926198890 @default.
- W1926198890 hasPrimaryLocation W19261988901 @default.
- W1926198890 hasRelatedWork W1979187129 @default.
- W1926198890 hasRelatedWork W2022303508 @default.
- W1926198890 hasRelatedWork W2055641651 @default.
- W1926198890 hasRelatedWork W2162342145 @default.
- W1926198890 hasRelatedWork W2387577256 @default.
- W1926198890 hasRelatedWork W2410213410 @default.
- W1926198890 hasRelatedWork W2417697013 @default.
- W1926198890 hasRelatedWork W2417951660 @default.
- W1926198890 hasRelatedWork W2418294778 @default.
- W1926198890 hasRelatedWork W2975801025 @default.
- W1926198890 hasVolume "2" @default.
- W1926198890 isParatext "false" @default.
- W1926198890 isRetracted "false" @default.
- W1926198890 magId "1926198890" @default.
- W1926198890 workType "article" @default.